Dechra Acquires Worldwide Rights to the Mirataz® Product Portfolio Further to the announcement on 17 March 2020, Dechra is pleased to announce that the acquisition of the worldwide rights of the Mirataz® product portfolio from Kindred Biosciences Incorporated has completed. The addition of Mirataz significantly enhances the Dechra portfolio and is fully complementary to its […]
Author Archive for: Bill.Cole@dechra.com
About Bill Cole
This author has yet to write their bio.Meanwhile lets just say that we are proud Bill Cole contributed a whooping 2 entries.
Entries by Bill Cole
The Board of Dechra is pleased to announce that it has agreed terms to acquire the worldwide rights to the Mirataz® product portfolio from Kindred Biosciences Incorporated for a total consideration of USD43.0 million (£35.0 million)1, and a royalty on future sales. The acquisition will be financed from the Group’s existing cash and borrowing facilities. […]
KindredBio proudly supports
Rabies Free Africa